This is the general strategy used for designing exon-skipping oligonucleotides for DMD; as there are 79 exons in the longest splice form of the dystrophin transcript, many different oligos are needed to address the range of mutations present in the population of people with DMD.
This is the general strategy. This general strategy is used for designing exon-skipping oligonucleotides for DMD. Many different oligos are needed to address the range of mutations present in the population of people with DMD. There are 79 exons in the longest splice form of the dystrophin transcript.